TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04289012

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Helicobacter Pylori screening by UBT
Description: The UBT is based on the fact that Hp produces urease, which catalyzes the urea molecule into ammonia (NH3) and carbon dioxide (CO2). After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (tube, bag or breath card). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and Hp diagnosis is made based on previously established cut-off levels for Hp infection.
Study: NCT01100827

Intervention type: OTHER
Intervention: EGFR mutation status in patients
Study: NCT02007915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate Disodium
Description: Pamidronate will be given intravenously over one hour, one day per month for three out of every four months. The initial dose is 0.5mg/kg and subsequent doses are 1mg/kg. Infusions will continue for at least one year with a second year possibly recommended by the surgeon from data on the x-ray and bone scan.
Study: NCT02745574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined maneuver
Description: Combined maneuver (Intraperitoneal normal saline infusion and Pulmonary recruitment maneuver): the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion
Description: the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity.
Study: NCT01239459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide HMR1726
Description: Pharmaceutical form:film coated tablet~Route of administration: oral administration on Day 1 under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide HMR1726
Description: Pharmaceutical form:film coated tablet~Route of administration: oral administration on Day 1 under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Pharmaceutical form:powder~Route of administration: oral administration 3 times per day on Day 54 and 55

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Pharmaceutical form:powder~Route of administration: oral administration 3 times per day on Day 54 and 55
Study: NCT02297139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study: NCT01924533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
Study: NCT03738930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI based mHealth system
Description: AI based mHealth system is used to deliver self-management contral message and health education message to make patients take notice of bleeding events after PCI.
Study: NCT04061785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Judo4Balance - 12 week judo inspired exercise program
Description: 12 weeks x 45 minute judo inspired exercise in lead by instructor in a group setting.
Study: NCT03072186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: near-infrared light nasal endoscope used with ICG
Description: Using the near-infrared light nasal endoscope with ICG will identify anatomical landmarks and and tumor characteristics to provide a clear demonstration of the blood supply.
Study: NCT02750995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NPMW-peptide vaccine
Description: Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.
Study: NCT02889419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evaluation of underwear Selfia®
Description: Patients are evaluated for a week using their usual underwear for the realization of SC. At the end of the week, they receive Selfia ® adaptated underwear and they use it for one week for a new evaluation. Finally, underwear will be given to patients and during follow-up consultations in routine at 6 months and 1 year, he will be asked if they reused or bought underwear.
Study: NCT00323063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study: NCT05512117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midline insertion
Description: Midline catheter insertion
Study: NCT01911949

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single shot femoral nerve block
Description: Nerve block in lingual crease using ultrasound guidance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single shot femoral nerve block
Description: Nerve block in lingual crease using ultrasound guidance
Study: NCT02009943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: One time dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Goal-directed dosing
Study: NCT02595658

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal composition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal composition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal composition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal composition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid-Acting Insulin Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid-Acting Insulin Dose
Study: NCT01641042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: 2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: 2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
Study: NCT01464567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T Tube Spontaneous Breathing Trial
Description: T Tube ventilation for 30 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation
Description: Pressure-Support Ventilation for 30 minutes
Study: NCT02125240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125 mg three times daily (375 mg per day) by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 tablet three times daily by mouth
Study: NCT02500251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belimumab
Description: Belimumab will be administered per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belimumab
Description: Belimumab will be administered per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Plasmapheresis will be administered per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Plasmapheresis will be administered per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Plasmapheresis will be administered per study protocol.
Study: NCT04547400

Intervention type: OTHER
Intervention: assessment
Description: Assessments of balance, gait, lower extremity position sense, and foot sole sense

Intervention type: OTHER
Intervention: assessment
Description: Assessments of balance, gait, lower extremity position sense, and foot sole sense
Study: NCT02230215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty with use of Visionaire Patient-Specific Instrumentation
Description: The manufacturing of a patient-specific instrument to be used by the orthopaedic surgeon during the knee replacement surgery.
Study: NCT03233074

Intervention type: OTHER
Intervention: Bone marrow analyses
Description: This is a non-interventional study for the constitution of a biobank of bone marrows, in order to further investigate in vitro the cellular properties of bone marrow-isolated mesenchymal stromal cells.
Study: NCT03383822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: Humalog lispro 40 IU intranasally
Study: NCT02266524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride, very low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride, medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride, high dose
Study: NCT02709317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Intervention
Study: NCT03383822

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Diluent intranasally
Study: NCT00606060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kogenate (BAY14-2222)
Description: 100 IU/mL (250 IU/vial nominal potency) continuous infusion over 6-11 days in 12 patients. 400 IU/mL (1000 IU/vial nominal potency) continuous infusion over 6-11days in 3 patients.
Study: NCT00490230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279396

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WR 279396
Study: NCT02709317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention
Study: NCT02240667

Intervention type: DRUG
Intervention: Dabigatran etexilate
Description: 150 mg or 110 mg capsules twice daily

Intervention type: DRUG
Intervention: Vitamin K antagonists
Description: International Normalized Ratio (INR) 2-3
Study: NCT00637013

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acromioplasty
Description: Arthroscopic or open acromioplasty
Study: NCT01791387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Patients will be treated with dovitinib (500 mg orally, once daily 5 days on/2 days off) until disease progression, intolerability, patient refusal, death or study drug discontinuation for any other reason. Dovitinib should be ingested at least 1 hour prior to a meal or at least 2 hours following a meal at approximately the same time each day.~If patients cannot tolerate the protocol-specified dosing schedule, dose reductions or treatment interruptions are permitted. When necessary, dovitinib may be reduced to 400 mg for 5 days on/2 days off. If an additional dose reduction is required, dovitinib may be reduced to 300 mg dose 5 days on/2 days off. Once dose is reduced due to an adverse event, it cannot be re-escalated. Patients are allowed only 2 dose reductions.
Study: NCT00359125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mifepristone (RU-486)
Description: RU-486, 600 mg/day for 1 week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 600 mg/day for 1 week.
Study: NCT00637013

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy according to a standardized protocol
Study: NCT03228745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative MBSR
Description: A MBSR program typically consists of 8 weekly 2.5 hour sessions, home practice (typically 45 minutes per day, 6 days per week), and one day retreat. During the program, participants engage in a number of mindfulness practices (e.g., body scan, mindful movement, meditation) and discussions of their experiences, with the aim enhancing awareness to moment-to-moment experiences in a non-judging and accepting manner.
Study: NCT00310544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnevist (Gadopentetate dimeglumine, BAY86-4882)
Description: One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnevist (Gadopentetate dimeglumine, BAY86-4882)
Description: One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
Study: NCT05720819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined biofeedback-virtual reality device
Description: The study's biofeedback-VR device was developed in collaboration with students and faculty at the University of Washington Global Innovation Exchange program. The system included an Oculus Go mobile VR headset (wireless, portable, head-mounted display, with screen providing a 101° field of view with 2560 x 1440 resolution at a 60-72 Hz frame rate; Oculus VR, LLC, Menlo Park, CA/USA) and with built-in speaker, in addition to a Polar H10 heart rate monitor (electrocardiogram, or ECG, to measure heart rate; Polar Electro Inc., Bethpage, NY/USA), with customized software programmed for the study using the Unity3D game engine (Unity Technologies, Bellevue, WA/USA). Individuals in the experimental arm are asked to use this device for 10 minutes daily, on at least 3 days per week.
Study: NCT01760902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Physical Activity
Description: The group will convene weekly for 12 consecutive weeks and monthly thereafter for 9 consecutive months. Thus, there will be a total of 21 group-based sessions over the one-year period
Study: NCT00302900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Donation Water Consumption
Description: Consumption of 500 ml of bottled water 30 minutes prior to donating

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Donation Water Consumption
Description: Consumption of 500 ml of bottled water 30 minutes prior to donating

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Tensing Exercise During Donation
Description: Alternating leg lifts at 10-second intervals during donation

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Muscle Tensing Exercise Prior to Donation
Description: Alternating leg lifts at 10-second intervals prior to insertion of the donation needle
Study: NCT04713072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-035
Description: ABY-035 solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-035
Description: ABY-035 solution for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to ABY-035 solution for injection
Study: NCT02607813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: pan-RAF inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: pan-RAF inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: pan-RAF inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: pan-RAF inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: pan-RAF inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: pan-RAF inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Biological: PDR001 anti-PD1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Biological: PDR001 anti-PD1 antibody
Study: NCT02596048

Intervention type: OTHER
Group type: OTHER
Intervention: Iomeron
Description: Iomeron or Imeron which is a iomeprol injection, hereafter referred to as iomeprol is an injectable solution of iomeprol, a non-ionic hydrosoluble iodinated compound used as a medical imaging contrast agent for radiological examinations.
Study: NCT01286129

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal allergen challenge
Description: Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal allergen challenge
Description: Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.
Study: NCT04390165

Intervention type: OTHER
Intervention: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances
Description: This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
Study: NCT00713076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182
Description: Lens Cleaning Solution Formulation Identification Number 109182
Study: NCT04128917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAPAE01
Description: RAPAE01/Clarithromycin/Amoxicillin BID peroral
Study: NCT00869960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: tenofovir 300 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine
Description: emtricitabine 200 mg on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: atazanavir 300mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir 100 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
Study: NCT00823654

Intervention type: OTHER
Intervention: Blood draw and questionnaires
Description: At the start of the study: blood draw, questionnaire and menstrual calendar ↓ Start planned therapy (or observation/surveillance) for cancer treatment~↓~Tests in the middle of chemotherapy (if applicable):~Blood draw and collection of monthly menstrual calendars ↓~Tests when chemotherapy is over (if applicable):~Blood draw and collection of monthly menstrual calendars~↓~Tests every 4 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire ↓~Tests every 6 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire~↓~Yearly follow-up for about 2 years:~Blood draw collection of monthly menstrual calendars, and questionnaire

Intervention type: OTHER
Intervention: Blood draw and questionnaires
Description: Study Schema for Unaffected High Risk Women with BRCA mutations Identify eligible premenopausal patients and obtain informed consent~↓ Register patients at Memorial Sloan-Kettering Cancer Center~↓ Baseline evaluation: Blood draw and baseline reproductive health and sexual questionnaires (Appendix A)/menstrual calendar (Appendix C)~↓ Annual follow-up x 4 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health and sexual health questionnaires~↓ Year 1 follow up Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires~↓ Optional annual follow-up years 2-5 Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires